News Conference News ESC 2025 BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension Todd Neale August 31, 2025
News Conference News ESC 2025 Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF Michael O'Riordan August 29, 2025
News Conference News ESC 2024 Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events Caitlin E. Cox August 31, 2024
News Conference News ESC 2023 ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran Michael O'Riordan September 01, 2023
News Conference News ESC 2023 New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground Caitlin E. Cox August 30, 2023
News Conference News ESC 2022 CV Care Around Noncardiac Surgery: New ESC Guidelines Michael O'Riordan September 07, 2022
News Conference News ESC 2022 Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke Todd Neale August 28, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Conference News ESC 2020 EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression Yael L. Maxwell September 02, 2020
News Conference News ESC 2019 Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories Yael L. Maxwell September 06, 2019
News Conference News ESC 2019 New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD Shelley Wood August 31, 2019
News Conference News ESC 2018 Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE Shelley Wood August 26, 2018
News Conference News ESC 2018 CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD Shelley Wood August 25, 2018
News Conference News ESC 2017 CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events Michael O'Riordan August 27, 2017
News Opinion Editor's Corner ESC 2017 ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On Shelley Wood August 18, 2017
News Conference News ESC 2016 Optimal Approach for BP Lowering Debated Amid New J-Curve Signals in Stable CAD Todd Neale September 09, 2016
News Conference News ESC 2016 Reversal Agent for Factor Xa Inhibitors Rapidly Reduces Anticoagulant Effects: ANNEXA-4 Todd Neale August 31, 2016
News Conference News ESC 2016 NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry Michael O'Riordan August 28, 2016
News Conference News ESC 2016 Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say Michael O'Riordan August 27, 2016